Insider Selling: Zynex Inc. (OTCMKTS:ZYXI) CFO Sells 13,750 Shares of Stock

Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead sold 13,750 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $8.25, for a total transaction of $113,437.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

OTCMKTS ZYXI traded up $0.43 during trading on Wednesday, hitting $8.65. 212,383 shares of the company’s stock were exchanged, compared to its average volume of 89,663. The company has a market cap of $251.19 million, a price-to-earnings ratio of 39.32 and a beta of 1.05. Zynex Inc. has a fifty-two week low of $2.40 and a fifty-two week high of $9.22.

Zynex (OTCMKTS:ZYXI) last issued its earnings results on Tuesday, April 30th. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $8.45 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. As a group, equities research analysts forecast that Zynex Inc. will post 0.28 EPS for the current year.



Hedge funds and other institutional investors have recently modified their holdings of the business. ExodusPoint Capital Management LP acquired a new position in shares of Zynex in the first quarter valued at approximately $45,000. Sigma Planning Corp acquired a new position in shares of Zynex in the first quarter valued at approximately $63,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Zynex in the first quarter valued at approximately $118,000. WealthTrust Axiom LLC acquired a new position in shares of Zynex in the first quarter valued at approximately $132,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Zynex in the first quarter valued at approximately $215,000. 0.05% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently weighed in on ZYXI shares. Zacks Investment Research raised shares of Zynex from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research report on Saturday, March 2nd. B. Riley reaffirmed a “buy” rating on shares of Zynex in a research report on Friday, February 22nd.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://dakotafinancialnews.com/2019/06/13/insider-selling-zynex-inc-otcmktszyxi-cfo-sells-13750-shares-of-stock.html.

About Zynex

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Further Reading: What are the benefits of a balanced fund?

Insider Buying and Selling by Quarter for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.